Advanced Filters
noise

Chemotherapy Clinical Trials

A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,512 clinical trials
S Saba Javed, M D

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study

To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.

18 years of age All Phase 0
T Takehiro Okabayashi

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP

The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.

18 - 85 years of age All Phase 2/3
J Jin Jie

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

A randomized,multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated AML as shown with overall survival compared to salvage chemotherapy, and also to investigate the efficacy of Clifutinib as assessed by CR/CRh rate in these subjects.

18 years of age All Phase 3
H Howard S. Hochster, MD

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

This phase II trial tests whether NBT-NM108 works in reducing chemotherapy-induced diarrhea in patients with colon cancer that has spread to other places in the body (metastatic). Irinotecan is one of the most used medicine for colon cancer, but it leads to diarrhea in most patients receiving it and among …

18 years of age All Phase 2
S Sebastian Eady

DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

The goal of this study is to test whether chemotherapy guided by a new imaging method named DCE-MRI can more effectively reduce a pancreatic tumor, enabling curable surgery, over the conventional method when a tumor is categorized as borderline resectable pancreatic cancer. UAB radiological research team has been studying a …

19 years of age All Phase N/A
H Huai Liu, MD

A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.

18 - 75 years of age All Phase 2
S Shira Dinner, MD

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.

18 years of age All Phase 2
N Nikita Mochkin, MD, PhD

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The primary objective is to assess efficacy, safety and progression-free survival (PFS) of different approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).

18 - 50 years of age All Phase 3
l lin yang

Ivonescimab Plus Chemotherapy in Patients with Initially Unresectable Colorectal Cancer Liver Metastases

The goal of this clinical trial is to learn if ivonescimab plus chemotherapy works to treat colorectal cancer liver metastases that cannot be completely removed. It will also learn about the safety of ivonescimab. The main questions it aims to answer are: Does ivonescimab plus chemotherapy raise the objective response …

18 years of age All Phase 2
Z Zhiming Zhuang

Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

This is a multicenter, open-label, prospective, single-arm, phase II study designed to evaluate the efficacy and safety of neoadjuvant zanidatamab combined with tislelizumab and chemotherapy, followed by selective bladder preservation, in patients with HER2-positive muscle-invasive bladder cancer (MIBC) staged cT2-4aN0-1M0.

18 - 85 years of age All Phase 2

Simplify language using AI